published meta-analysis   sensitivity analysis   studies

IFN alpha in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsPandit, 2021 0.95 [0.02; 50.33] Shashi Bhushan, 2021 4.39 [0.20; 98.33] 2.45[0.21; 28.37]Pandit, 2021, Shashi Bhushan, 202120%289moderatenot evaluable deathsdetailed resultsPandit, 2021 0.95 [0.02; 50.33] Shashi Bhushan, 2021 4.39 [0.20; 98.33] 2.45[0.21; 28.37]Pandit, 2021, Shashi Bhushan, 202120%289moderatenot evaluable clinical improvementdetailed resultsShashi Bhushan, 2021 0.68 [0.21; 2.20] 0.68[0.21; 2.20]Shashi Bhushan, 202110%242NAnot evaluable clinical improvement (14-day)detailed resultsPandit, 2021 8.77 [0.94; 81.67] Shashi Bhushan, 2021 0.68 [0.21; 2.20] 2.03[0.17; 24.32]Pandit, 2021, Shashi Bhushan, 2021275%281moderatenot evaluable clinical improvement (7-day)detailed resultsShashi Bhushan, 2021 1.91 [1.03; 3.53] 1.91[1.03; 3.53]Shashi Bhushan, 202110%222NAnot evaluable viral clearance detailed resultsPandit, 2021 2.33 [0.55; 9.83] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 2.69[1.48; 4.87]Pandit, 2021, Shashi Bhushan, 202120%281moderatenot evaluable viral clearance by day 14detailed resultsPandit, 2021 10.23 [1.12; 93.35] Shashi Bhushan, 2021 0.00 [0.00; 0.01] 0.18[0.00; 435.69]Pandit, 2021, Shashi Bhushan, 2021298%1,359moderatenot evaluable viral clearance by day 7detailed resultsPandit, 2021 2.33 [0.55; 9.83] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 2.69[1.48; 4.87]Pandit, 2021, Shashi Bhushan, 202120%281moderatenot evaluable serious adverse eventsdetailed resultsPandit, 2021 0.95 [0.02; 50.33] 0.95[0.02; 50.33]Pandit, 202110%39NAnot evaluable adverse eventsdetailed resultsPandit, 2021 1.68 [0.47; 5.97] 1.68[0.47; 5.97]Pandit, 202110%39NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-28 17:21 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 899,1235 - roots T: 290